Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/676"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_type | |
| ?:Evidence_value | |
| ?:content |
"route of administration: oral
study duration: single oral doses of ziprasidone 40 mg on three occasions at least 7 days apart. On one occasion ziprasidone was administered alone, on another occasion ziprasidone was co-administered with oral cimetidine 800 mg and on a third occasion ziprasidone was co-administered with oral Maalox1.
population: 11 healthy young subjects, 9 female, 3 male (only 10 completed the cimetidine - ziprasidone study)
tested for known CYP450 polymorphisms?
ages: 18-45
description:
Results The administration of cimetidine increased the ziprasidone AUC(0,inf) by 6% but there were no statistically significant differences in Cmax, tmax or lambda_z between the ziprasidone + cimetidine group and the ziprasidone group."
|
| dc:creator | |
| dc:date |
"09/22/2009 18:37:28"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ cimetidine_increases_auc_ziprasidone, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1770 }